• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Coya Therapeutics, Inc. - Common Stock (NQ:COYA)

3.110 -0.120 (-3.72%)
Delayed Quote Updated: 4:00 PM EST, Nov 3, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 518,218
Open 3.260
Bid (Size) 3.030 (100)
Ask (Size) 4.250 (1,000)
Prev. Close 3.230
Today's Range 3.030 - 3.405
52wk Range 3.030 - 6.620
Shares Outstanding 9,947,915
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Coya Therapeutics to Present Neurofilament Light Chain (NfL) Biomarker Stratification Methodology in the ALSTARS Trial to Minimize the Impact of Heterogeneity in ALS Clinical Trials at the 2026 Annual NEALS Meeting
October 28, 2026
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Coya to Initiate Open-Label Extension of Phase 2/3 ALSTARS Trial of COYA 302 in ALS
October 14, 2026
From Coya Therapeutics, Inc.
Via Business Wire

Performance

52-Week Range 53.0% below 52-week high
3.110
3.0352W Low 6.6252W High
1 Week 27.7% below 1-week high
3.031W Low 4.301W High

Coya Therapeutics, Inc. - Common Stock (COYA) traded between $3.03 and $6.62 over the past 52 weeks and last traded at $3.11, 53.0% below its 52-week high. Over the past week it ranged between $3.03 and $4.30.

Past 12 Months
-24.5%
-35.9%
-29.8%
-27.0%
-45.0%
-48.2%
1W -$1.01
1M -$1.74
3M -$1.32
6M -$1.15
YTD -$2.54
1Y -$2.89

COYA was -48.2% over the past year, -27.0% over six months, -45.0% year to date, -24.5% in the last week.

12 Months vs Market
COYA
-48.2%
DIA
+9.2%
SPY
+10.4%
QQQ
+8.4%
IWM
+14.0%

Over the past 12 months COYA returned -48.2% versus DIA (Dow) +9.2%, SPY (S&P 500) +10.4%, QQQ (Nasdaq 100) +8.4% and IWM (Russell 2000) +14.0%.

Volume & Liquidity 3.73× 3-mo avg
Today 518,218 3-mo avg 138.9K
1W
213.3K
1M
159.4K
3M
138.9K
6M
172.9K
YTD
178.2K
1Y
180.3K

COYA most recently traded 518,218 shares against a 3-month average daily volume of 138.9K.

More News

Read More
News headline image
Coya Therapeutics Announces Participation at Chardan's 10th Annual Healthcare Conference
October 13, 2026
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Coya Therapeutics Announces Completion of Full Enrollment in Phase 2/3 ALSTARS Trial of COYA 302 for the Treatment of ALS
October 05, 2026
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Coya Therapeutics Announces Enrollment of 100th Participant in Phase 2/3 ALSTARS Trial of COYA 302 for the Treatment of ALS
September 15, 2026
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Coya Therapeutics Announces Publication of Preclinical Study Demonstrating Combination Immunomodulatory Effects of COYA 303 in a Well-Established Model of Peripheral and CNS Inflammation
September 08, 2026
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Coya Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update
August 11, 2026
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Coya Therapeutics to Present ALSTARS Trial Design at the ENCALS 2026 Meeting
June 18, 2026
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Coya Therapeutics to Host Virtual Webinar on the Intersection of Repetitive Head Trauma, Brain Inflammation and Neurodegenerative Disease
June 15, 2026
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Coya Therapeutics Announces the First Cohort of Patients in the ALSTARS Trial Have Begun the Blinded Active-Treatment Extension Phase
June 08, 2026
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Coya Therapeutics to Present ALSTARS Trial Design at the 5th ALS Drug Development Summit
May 27, 2026
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Coya Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update
May 12, 2026
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Coya Therapeutics Has Been Granted U.S. FDA Fast Track Designation for COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
May 12, 2026
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Coya Therapeutics Announces Publication Demonstrating Correlation Between Longitudinal Biomarker Data and Clinical Outcomes Supporting the Mechanistic Rationale for COYA 302 in Patients with ALS
April 09, 2026
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Coya Therapeutics Announces Planned Board Transition and Appointment of Mark H. Pavao as Independent Director
April 02, 2026
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Coya Therapeutics Announces Publication Demonstrating Regulatory T-Cell Dysfunction and Systemic Inflammation in Frontotemporal Dementia, Supporting Mechanistic Rationale for COYA 302 Immune-Restoring Therapy
March 18, 2026
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2025 Financial Results
March 16, 2026
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Coya Therapeutics to Host Webinar with Leading Medical Experts on Amyotrophic Lateral Sclerosis (ALS) Drug Development, Patient Landscape, and Ongoing Clinical Trial
February 10, 2026
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Coya Therapeutics Announces $11.1 Million Private Placement
January 30, 2026
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Coya Therapeutics CEO Dr. Arun Swaminathan Issues Letter to Stockholders
January 20, 2026
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Coya Therapeutics Announces Results of Investigator-Initiated Study of LD IL-2 and CTLA4-Ig Demonstrating Treg Enhancement and Cognitive Stability in Frontotemporal Dementia Patients
January 08, 2026
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Coya Therapeutics Announces U.S. FDA Acceptance of Investigational New Drug (IND) Application for COYA 302 for the Treatment of Frontotemporal Dementia (FTD)
January 05, 2026
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Coya Therapeutics Receives Clinical Trial Application (CTA) Acceptance from Health Canada to Proceed with the COYA 302 ALSTARS Trial for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
December 23, 2025
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Coya Therapeutics Announces Patients Have Been Dosed in the ALSTARS Trial of COYA 302 for the Treatment of ALS
December 09, 2025
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Coya Therapeutics to Participate in Upcoming Investor Relations and Clinical Trials Conferences
November 25, 2025
From Coya Therapeutics, Inc.
Via Business Wire

Frequently Asked Questions

Is Coya Therapeutics, Inc. - Common Stock publicly traded?
Yes, Coya Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Coya Therapeutics, Inc. - Common Stock trade on?
Coya Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Coya Therapeutics, Inc. - Common Stock?
The ticker symbol for Coya Therapeutics, Inc. - Common Stock is COYA on the Nasdaq Stock Market
What is the current price of Coya Therapeutics, Inc. - Common Stock?
The current price of Coya Therapeutics, Inc. - Common Stock is 3.110
When was Coya Therapeutics, Inc. - Common Stock last traded?
The last trade of Coya Therapeutics, Inc. - Common Stock was at 11/03/26 04:00 PM ET
What is the market capitalization of Coya Therapeutics, Inc. - Common Stock?
The market capitalization of Coya Therapeutics, Inc. - Common Stock is 30.94M
How many shares of Coya Therapeutics, Inc. - Common Stock are outstanding?
Coya Therapeutics, Inc. - Common Stock has 31M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap